View Item 

Show simple item record

Decreased expression of V‐set and immunoglobulin domain containing 1 (VSIG1) is associated with poor prognosis in primary gastric cancer
dc.contributor.authorChen, Yibingen_US
dc.contributor.authorPan, Keen_US
dc.contributor.authorLi, Shengpingen_US
dc.contributor.authorXia, Jianchuanen_US
dc.contributor.authorWang, Weien_US
dc.contributor.authorChen, Jugaoen_US
dc.contributor.authorZhao, Jingjingen_US
dc.contributor.authorLü, Linen_US
dc.contributor.authorWang, Dandanen_US
dc.contributor.authorPan, Qiuzhongen_US
dc.contributor.authorWang, Qijingen_US
dc.contributor.authorLi, Yongqiangen_US
dc.contributor.authorHe, Jiaen_US
dc.contributor.authorLi, Qiaoen_US
dc.date.accessioned2012-08-09T14:55:13Z
dc.date.available2013-10-18T17:47:30Zen_US
dc.date.issued2012-09-01en_US
dc.identifier.citationChen, Yibing; Pan, Ke; Li, Shengping; Xia, Jianchuan; Wang, Wei; Chen, Jugao; Zhao, Jingjing; Lü, Lin ; Wang, Dandan; Pan, Qiuzhong; Wang, Qijing; Li, Yongqiang; He, Jia; Li, Qiao (2012). "Decreased expression of Vâ set and immunoglobulin domain containing 1 (VSIG1) is associated with poor prognosis in primary gastric cancer ." Journal of Surgical Oncology 106(3): 286-293. <http://hdl.handle.net/2027.42/92382>en_US
dc.identifier.issn0022-4790en_US
dc.identifier.issn1096-9098en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/92382
dc.description.abstractBackground To date, the significance of altered expression of V‐set and immunoglobulin domain containing 1 (VSIG1) in gastric cancer has not yet been elucidated. Methods We examined VSIG1 expression in 30 paired gastric cancer tissues and noncancerous gastric mucosa as well as in 5 gastric cancer cell lines by real‐time PCR and Western blotting. In addition, we analyzed VSIG1 expression in 232 gastric adenocarcinoma samples by immunohistochemistry. Results VSIG1 expression was significantly reduced at both the mRNA and protein levels in gastric cancer tissues. Immunohistochemistry revealed that VSIG1 expression was completely lost in 126 out of the 232 (54.3%) patient samples and remarkably reduced in another 106 (45.7%) patients. Negative VSIG1 expression was significantly correlated with tumor size ( P  = 0.007), T ( P  = 0.023), and M stage ( P  = 0.037). Importantly, loss of VSIG1 expression was significantly correlated with poor overall survival (OS, P  < 0.001) and disease‐free survival (DFS, P  = 0.006) in gastric cancer patients. Cox regression analyses showed that VSIG1 expression was an independent predictor of OS ( P  = 0.002) and DFS ( P  = 0.039). Conclusions Our findings suggest that silencing VSIG1 may play an important role in gastric carcinogenesis and that VSIG1 may serve as a prognostic marker as well as a potential therapeutic target for gastric cancer. J. Surg. Oncol. 2012; 106:286–293. © 2011 Wiley Periodicals, Inc.en_US
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherGastric Canceren_US
dc.subject.otherVSIG1en_US
dc.subject.otherReal‐Time Quantitative PCRen_US
dc.subject.otherWestern Blottingen_US
dc.subject.otherImmunohistochemistryen_US
dc.subject.otherCox Regressionen_US
dc.titleDecreased expression of V‐set and immunoglobulin domain containing 1 (VSIG1) is associated with poor prognosis in primary gastric canceren_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelSurgery and Anesthesiologyen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Surgery, University of Michigan Medical Center, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Surgery, University of Michigan Medical Center, 1520A MSRB‐1, Ann Arbor, MI 48109‐0666. Fax: 734‐763‐4135.en_US
dc.contributor.affiliationotherDepartment of Hepatobiliary Surgery, Sun Yat‐Sen University Cancer Center, Guangzhou, Chinaen_US
dc.contributor.affiliationotherState Key Laboratory of Oncology in Southern China and Department of Experimental Research, Sun Yat‐Sen University Cancer Center, Guangzhou, Chinaen_US
dc.contributor.affiliationotherState Key Laboratory of Oncology in Southern China and Department of Experimental Research, Sun Yat‐Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, China. Fax: +86‐20‐87343392.en_US
dc.contributor.affiliationotherDepartment of Gastric and Pancreatic Surgery, Sun Yat‐Sen University Cancer Center, Guangzhou, Chinaen_US
dc.identifier.pmid22095633en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/92382/1/22150_ftp.pdf
dc.identifier.doi10.1002/jso.22150en_US
dc.identifier.sourceJournal of Surgical Oncologyen_US
dc.identifier.citedreferenceAnders M, Vieth M, Rocken C, et al.: Loss of the Coxsackie and adenovirus receptor contributes to gastric cancer progression. Br J Cancer 2009; 100: 352 – 359.en_US
dc.identifier.citedreferenceJemal A, Bray F, Center MM, et al.: Global cancer statistics. CA Cancer J Clin 2011; 61: 69 – 90.en_US
dc.identifier.citedreferencePolk DB, Peek RM, Jr.: Helicobacter pylori: Gastric cancer and beyond. Nat Rev Cancer 2010; 10: 403 – 414.en_US
dc.identifier.citedreferenceUshijima T, Sasako M: Focus on gastric cancer. Cancer Cell 2004; 5: 121 – 125.en_US
dc.identifier.citedreferenceTamura G: Alterations of tumor suppressor and tumor‐related genes in the development and progression of gastric cancer. World J Gastroenterol 2006; 12: 192 – 198.en_US
dc.identifier.citedreferenceTakeno A, Takemasa I, Doki Y, et al.: Integrative approach for differentially overexpressed genes in gastric cancer by combining large‐scale gene expression profiling and network analysis. Br J Cancer 2008; 99: 1307 – 1315.en_US
dc.identifier.citedreferenceMyllykangas S, Junnila S, Kokkola A, et al.: Integrated gene copy number and expression microarray analysis of gastric cancer highlights potential target genes. Int J Cancer 2008; 123: 817 – 825.en_US
dc.identifier.citedreferenceMakrilia N, Kollias A, Manolopoulos L, et al.: Cell adhesion molecules: Role and clinical significance in cancer. Cancer Invest 2009; 27: 1023 – 1037.en_US
dc.identifier.citedreferenceGuilford P, Hopkins J, Harraway J, et al.: E‐cadherin germline mutations in familial gastric cancer. Nature 1998; 392: 402 – 405.en_US
dc.identifier.citedreferencePerl AK, Wilgenbus P, Dahl U, et al.: A causal role for E‐cadherin in the transition from adenoma to carcinoma. Nature 1998; 392: 190 – 193.en_US
dc.identifier.citedreferenceCavallaro U, Christofori G: Cell adhesion and signalling by cadherins and Ig‐CAMs in cancer. Nat Rev Cancer 2004; 4: 118 – 132.en_US
dc.identifier.citedreferenceLi SG, Ye ZY, Zhao ZS, et al.: Correlation of integrin beta3 mRNA and vascular endothelial growth factor protein expression profiles with the clinicopathological features and prognosis of gastric carcinoma. World J Gastroenterol 2008; 14: 421 – 427.en_US
dc.identifier.citedreferenceGonzalez‐Mariscal L, Lechuga S, Garay E: Role of tight junctions in cell proliferation and cancer. Prog Histochem Cytochem 2007; 42: 1 – 57.en_US
dc.identifier.citedreferenceGutwein P, Schramme A, Voss B, et al.: Downregulation of junctional adhesion molecule‐A is involved in the progression of clear cell renal cell carcinoma. Biochem Biophys Res Commun 2009; 380: 387 – 391.en_US
dc.identifier.citedreferenceNaik MU, Naik TU, Suckow AT, et al.: Attenuation of junctional adhesion molecule‐A is a contributing factor for breast cancer cell invasion. Cancer Res 2008; 68: 2194 – 2203.en_US
dc.identifier.citedreferenceLamagna C, Hodivala‐Dilke KM, Imhof BA, et al.: Antibody against junctional adhesion molecule‐C inhibits angiogenesis and tumor growth. Cancer Res 2005; 65: 5703 – 5710.en_US
dc.identifier.citedreferenceJung H, Jun KH, Jung JH, et al.: The expression of claudin‐1, claudin‐2, claudin‐3, and claudin‐4 in gastric cancer tissue. J Surg Res 2011; 167: e185 – 191.en_US
dc.identifier.citedreferenceChang TL, Ito K, Ko TK, et al.: Claudin‐1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology 2010; 138: 255 – 265, e251–253.en_US
dc.identifier.citedreferenceAgarwal R, Mori Y, Cheng Y, et al.: Silencing of claudin‐11 is associated with increased invasiveness of gastric cancer cells. PLoS ONE 2009; 4: e8002.en_US
dc.identifier.citedreferencePark JY, Park KH, Oh TY, et al.: Up‐regulated claudin 7 expression in intestinal‐type gastric carcinoma. Oncol Rep 2007; 18: 377 – 382.en_US
dc.identifier.citedreferenceOshima T, Miwa H, Joh T: Aspirin induces gastric epithelial barrier dysfunction by activating p38 MAPK via claudin‐7. Am J Physiol Cell Physiol 2008; 295: C800 – C806.en_US
dc.identifier.citedreferenceScanlan MJ, Ritter G, Yin BW, et al.: Glycoprotein A34, a novel target for antibody‐based cancer immunotherapy. Cancer Immun 2006; 6: 2.en_US
dc.identifier.citedreferenceJunnila S, Kokkola A, Mizuguchi T, et al.: Gene expression analysis identifies over‐expression of CXCL1, SPARC, SPP1, and SULF1 in gastric cancer. Genes Chromosomes Cancer 2010; 49: 28 – 39.en_US
dc.identifier.citedreferenceShimada Y: JGCA (The Japan Gastric Cancer Association). Gastric cancer treatment guidelines. Jpn J Clin Oncol 2004; 34: 58.en_US
dc.identifier.citedreferenceHamilton SR, Aaltonen LA, editors. WHO classification of tumours. Tumours of the digestive system. Lyon: IARC Press; 2000.en_US
dc.identifier.citedreferenceSobin LH, Gospodarowicz MK, Wikkekind C, editors. TNM classification of malignant tumours. Hoboken: Wiley‐Blackwell; 2009.en_US
dc.identifier.citedreferenceHartgrink HH, Jansen EP, van Grieken NC, et al.: Gastric cancer. Lancet 2009; 374: 477 – 490.en_US
dc.identifier.citedreferenceYonemura Y, Endou Y, Kimura K, et al.: Inverse expression of S100A4 and E‐cadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res 2000; 6: 4234 – 4242.en_US
dc.identifier.citedreferenceYonemura Y, Ninomiya I, Kaji M, et al.: Decreased E‐cadherin expression correlates with poor survival in patients with gastric cancer. Anal Cell Pathol 1995; 8: 177 – 190.en_US
dc.identifier.citedreferenceYasui W, Oue N, Aung PP, et al.: Molecular–pathological prognostic factors of gastric cancer: A review. Gastric Cancer 2005; 8: 86 – 94.en_US
dc.identifier.citedreferenceOhtani S, Terashima M, Satoh J, et al.: Expression of tight‐junction‐associated proteins in human gastric cancer: Downregulation of claudin‐4 correlates with tumor aggressiveness and survival. Gastric Cancer 2009; 12: 43 – 51.en_US
dc.identifier.citedreferenceSanada Y, Oue N, Mitani Y, et al.: Down‐regulation of the claudin‐18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J Pathol 2006; 208: 633 – 642.en_US
dc.identifier.citedreferenceKim E, Lee Y, Kim JS, et al.: Extracellular domain of V‐set and immunoglobulin domain containing 1 (VSIG1) interacts with sertoli cell membrane protein, while its PDZ‐binding motif forms a complex with ZO‐1. Mol Cells 2010; 30: 443 – 448.en_US
dc.identifier.citedreferenceEbnet K, Suzuki A, Ohno S, et al.: Junctional adhesion molecules (JAMs): More molecules with dual functions? J Cell Sci 2004; 117: 19 – 29.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
22150_ftp.pdf
Size:
517.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.